Documentation Strategy for Zepbound (Tirzepatide) Prior Authorization in Obese Patients with OSA

Essential Documentation Elements

The American Thoracic Society recommends that patients with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with OSA as a weight-related comorbidity, who have failed or inadequately responded to comprehensive lifestyle intervention, require anti-obesity pharmacotherapy for OSA management 1, 2, 3
Patients should have a documented specific BMI value (must be ≥27 kg/m² with OSA, or ≥30 kg/m² without additional comorbidities) 1, 2, 3
A comprehensive lifestyle intervention trial should be documented, including reduced-calorie diet, exercise/increased physical activity, and behavioral counseling for an adequate duration (typically 3-6 months minimum) 1, 2
Inadequate response to lifestyle intervention should be quantified, including specific weight loss achieved (if <5% at 3 months or insufficient to improve OSA) and persistent OSA symptoms or elevated AHI despite lifestyle modifications 1, 2, 4

The American Thoracic Society conditionally recommends evaluation for anti-obesity pharmacotherapy in patients with OSA and BMI ≥27 kg/m² whose weight has not improved despite comprehensive lifestyle intervention 1, 2

Patients with OSA and BMI ≥27 kg/m² who have inadequate response to lifestyle intervention are appropriate candidates for anti-obesity pharmacotherapy, according to American Thoracic Society guidelines 1, 2, 3

Cardiovascular and metabolic comorbidities (if present) should be documented, including hypertension, type 2 diabetes, dyslipidemia, or cardiovascular disease, as these strengthen the indication for weight management 1, 4, 3
Quality of life impact should be documented, including specific functional impairments from OSA and obesity affecting daily activities, work performance, or safety (e.g., driving risk) 1, 2
Contraindications should be ruled out, including explicit statements of "no active cardiovascular disease" and "no contraindications to GLP-1/GIP receptor agonist therapy" 5, 3

The American Thoracic Society recommends that tirzepatide is FDA-approved for treatment of moderate-to-severe OSA in adults with obesity, which strengthens the medical necessity argument 3
A monitoring plan should be documented, including regular assessments of weight, BMI, and OSA symptoms, with follow-up sleep studies planned to evaluate AHI and oxygen saturation improvements 3

Semaglutide (Wegovy) is FDA‑approved only for obesity management and does not carry a specific indication for obstructive sleep apnea treatment. 6

In phase‑3 obesity trials, tirzepatide produced mean weight loss of ≈ 20.9 % at 72 weeks with the 15 mg dose, ≈ 19.5 % with the 10 mg dose, and ≈ 15.0 % with the 5 mg dose, compared with ≈ 3.1 % weight loss for placebo. Evidence derived from a large, double‑blind, randomized controlled trial (high‑quality). 6
Long‑term use of tirzepatide is recommended together with lifestyle modification because weight regain commonly occurs after drug cessation; thus, continued therapy may be required indefinitely. Based on trial follow‑up data (moderate‑to‑high certainty). 6

Liraglutide (a GLP‑1 agonist) reduced the apnea‑hypopnea index by ≈ 6.1 events/hour in the SCALE trial of patients with OSA, but the evidence quality was limited by industry funding and high dropout rates. (Low‑quality evidence). 7
Semaglutide demonstrated a 20 % reduction in major adverse cardiovascular events (MACE) in the SELECT trial, indicating superior cardiovascular outcomes; however, it lacks a specific FDA indication for sleep apnea. (High‑quality RCT evidence). 6